A safety warning has been issued regarding weight-loss drugs linked to mental health risks. The Therapeutic Goods Administration (TGA) of Australia has updated its product information for a class of medicines known as GLP-1 receptor agonists, which are commonly prescribed for type 2 diabetes and obesity. This update highlights an increased risk of potential suicidal ideation associated with these medications.
Among the drugs included in this warning is semaglutide, marketed in Australia as Ozempic. While primarily used as a treatment for diabetes, Ozempic has gained popularity for weight loss, especially among celebrities. Other GLP-1 receptor agonists affected by the TGA’s announcement include semaglutide sold under the brand name Wegovy, liraglutide (Saxenda), dulaglutide (Trulicity), and tirzepatide (Mounjaro).
The TGA has urged patients using these medications to consult their healthcare professionals if they experience new or worsening symptoms of depression, suicidal thoughts, or any unusual changes in mood or behavior. This caution follows investigations by the TGA and other international regulatory bodies.
Updates on Tirzepatide and Contraceptive Risks
In addition to the mental health warning, the TGA has revised the product information for tirzepatide (Mounjaro) to include a risk of decreased effectiveness of oral contraceptives when starting or increasing the dosage of the drug. As a precaution, patients taking tirzepatide are advised to switch to a non-oral contraceptive method or use a barrier method for four weeks after initiating treatment and for four weeks following any dose increases.
The TGA further emphasized that no GLP-1 receptor agonists should be used during pregnancy. Individuals with the potential for child-bearing are advised to implement effective contraception while using these medications.
The TGA’s warning highlights the importance of monitoring mental health and reproductive health while using these increasingly popular weight-loss drugs. For those in need of support, resources are available through Lifeline at 13 11 14 and Beyond Blue at 1300 22 4636.
